Valis Bioscience
Valis Bioscience is a private clinical research technology company that sells the ValisR platform and proprietary measurement tools, including remote video assessment, ACAM, ePRO/eDiary, and rater training, directly to pharmaceutical and biotech sponsors running psychiatric, neurological, psychedelic, and rare/orphan CNS clinical trials.
- Company typePrivate
- Founded2016
- HeadquartersBerkeley, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Valis Bioscience does
Valis Bioscience is a privately held clinical research technology company founded in 2016 and headquartered in Great Neck, NY, with additional offices in Berkeley, CA and New York, NY. The company develops a proprietary technology platform, branded ValisR, and a suite of digital measurement tools purpose-built for psychiatric and neurological disorder clinical trials, with stated specialization in psychedelic trials and rare/orphan CNS diseases. Its product portfolio includes the ACAM (Advanced Centralized Assessment Module) combining provisioned hardware and BYOD software for rater-administered video capture and independent scoring of clinical assessment visits, HIPAA-compliant remote video assessment solutions actively deployed in multiple Phase-III clinical trials, custom ePRO/eDiary applications, rater training and certification services delivered through the Trial.training portal, proprietary video capture and surveillance hardware/software, and bespoke mobile health application deployments. All digital tools are validated against HIPAA, GDPR, CCPA, 21 CFR Part 11, and the EU-U.S. Data Privacy Framework, with active listing on the DPF Program.
The company generates revenue through enterprise licensing of its technology platform on a recurring basis, supplemented by professional services revenue from rater training, eLearning, certification management, scientific consulting, and custom mHealth application deployment. Valis sells directly to pharmaceutical companies, biotech firms, and clinical trial sponsors through an enterprise field sales motion, targeting buyers developing compounds in CNS, psychedelic, and rare/orphan therapeutic areas. The company is led by CEO Ivan Goldensohn and co-founder/CSO Dr. Christian Yavorsky, who co-chairs the Rapid Acting Anti-Depressants Working Group at ISCTM, positioning the firm as scientist-led. Notable operational partners and collaborators include Aural Analytics (voice analytics), Medable (decentralized trial platform), NetraMark (AI/ML clinical data analysis), and NYU researcher Dr. Kelley O'Donnell on ketamine measurement standardization.
Valis Bioscience firmographics
Firmographics- Name
- Valis Bioscience
- Legal name
- Valis Bioscience, Inc.
- Website
- https://valisbioscience.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Valis Bioscience is a private clinical research technology company that sells the ValisR platform and proprietary measurement tools, including remote video assessment, ACAM, ePRO/eDiary, and rater training, directly to pharmaceutical and biotech sponsors running psychiatric, neurological, psychedelic, and rare/orphan CNS clinical trials.
- Ownership category
- akta.pro rank
Valis Bioscience industry classification
Industry- Product category
- Clinical Trial Technology (eClinical / CNS measurement)
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)
Keywords
Where Valis Bioscience is headquartered
LocationHeadquarters
- HQ city
- Berkeley
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Valis Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Technology Platform Licensing: Licensing of proprietary technology platform including remote video assessment, ePRO/eDiary solutions, and video capture solutions to clinical trial sponsors. Platform is deployed in Phase-III clinical trials.
- Professional Services - Rater Training: Industry leading rater training, eLearning, certification management, and scientific consulting services provided to pharma companies and clinical trial organizations.
- Mobile Health Application Deployment: Proprietary and custom deployment of mobile health applications for clinical trials, including bespoke outcome measures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Valis Bioscience product offering
Product offeringCore offering
Valis Bioscience develops and licenses proprietary clinical research technology for psychiatric and neurological disorder trials, centered on the ValisR digital health platform. Its offerings include a HIPAA-compliant remote video assessment platform, the ACAM hardware+software video capture and scoring module, custom ePRO/eDiary applications, rater training and certification via the Trial.training portal, mobile health applications, and scientific/endpoint consulting services sold to pharmaceutical companies, biotech firms, and clinical trial sponsors.
Product overview
Valis Bioscience offers a unified platform-plus-modules portfolio centered on the ValisR platform for measuring psychiatric and neurological disorders. The core platform is supplemented by specialized products including ACAM (hardware/software video capture and scoring), Remote Assessment Solutions (HIPAA-compliant remote video), and ePRO/eDiary (custom electronic patient-reported outcomes). Complementary services include Rater Training and Certification, Scientific Consulting, and proprietary mHealth Applications for digital therapeutics and adverse event prevention. The suite is designed for psychedelic trials, rare and orphan CNS disorders, and decentralized clinical trials, with all digital tools validated against HIPAA, GDPR, CCPA, 21 CFR Part 11, and EU-U.S. Data Privacy Framework.
Differentiator
Problem solved
Functional benefit
Brands
- ACAM: A streamlined hardware and software solution for secure, rater-friendly recording of assessment visits.
- ValisR
- Trial.training
Products and services
- ValisR Platform Primary digital health platform that builds new digital tools to measure psychiatric and neurological disorders, integrating AI, decentralized clinical trial capabilities, and HIPAA/GDPR/21 CFR Part 11 compliant tools for mental health measurement in clinical trials. Sold to pharmaceutical companies, biotech firms, and clinical trial sponsors.
- ACAM (Advanced Centralized Assessment Module) Streamlined hardware (provisioned device) and software (BYOD) solution for secure, rater-friendly recording of clinical assessment visits, with a portal for assigning, reviewing, and independently scoring recordings. Regulatory compliant and branded per sponsor use, deployable on aggressive trial timelines. Sold to clinical trial sponsors.
- Remote Assessment Solutions HIPAA-compliant remote video platform solution actively deployed in multiple Phase-III clinical trials for conducting psychiatric and neurological assessments remotely. Sold to clinical trial sponsors running decentralized trials.
- ePRO / eDiary Solutions Custom eDiary and ePRO solutions deployed in weeks, designed by SME clinicians, with validation support on new measures. Includes training applications, mobile refresher courses, and eCertification for clinical trial sites. Sold to clinical trial sponsors.
- Rater Training and Certification Industry-leading rater training, eLearning, and certification management services delivered via the Trial.training portal. Includes subject/caregiver education, learning management systems, and SME-led programs targeting data inconsistency in clinical trials. Sold to pharmaceutical companies and clinical trial sponsors.
- Video Capture and Surveillance Solution Proprietary video capture and surveillance solution combining hardware and software components for documenting and monitoring clinical trial assessments. Sold to clinical trial sponsors.
- mHealth Applications Proprietary and custom deployment of mobile health applications for data collection, digital therapeutics, and patient monitoring in clinical trials. Sold to pharmaceutical companies and clinical trial sponsors.
- Scientific Consulting Endpoint selection, management, and development plus scientific consulting services for clinical trial design and execution, provided by SME clinicians. Sold to pharmaceutical companies and clinical trial sponsors.
Quantifiable outcome
- Remote video platform actively deployed in multiple Phase-III clinical trials
- +1 more outcomes
Companies that use Valis Bioscience
Customer profileSegments3 records
Ideal customer profiles2 records
Valis Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Valis Bioscience partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor.
- Cerevel TherapeuticsminorCerevel hosted a reception at CNS Summit 2019. Cerevel is a biotech company developing neuroscience therapies.
- NYU / Dr. Kelley O'DonnellminorCollaboration with NYU researcher Dr. Kelley O'Donnell on standardization of measurement outcomes in ketamine treatment at KRIYA Conference. Co-presentation on clinical measurement standardization.
- Betty-Jean Woodaman FoundationminorWoody's annual fundraising event for the Betty-Jean Woodaman foundation was held at CNS Summit 2019. Valis supports this scholarship foundation.
- NIH / NIMH / NIAAAminorValis CEO met with representatives from NIH, NIMH, and NIAAA at ACNP Annual Meeting 2019. These are key federal health research agencies involved in CNS research.
Scale indicators2 records
Recent moves1 record
Expansion highlights5 records
Valis Bioscience competitors and assessment
Company assessmentEmerging players
- Aural Analytics: Aural Analytics provides AI-driven voice and speech biomarkers for neurological and psychiatric clinical trials. It is an existing Valis collaboration partner at the CNS Summit, making it a closely related emerging player in CNS digital measurement rather than a direct eCOA competitor.
- Medable: Medable is a decentralized clinical trial platform partnering with sponsors on eConsent, eCOA, and remote monitoring. Valis has an established partnership dialog with Medable, indicating direct overlap in DCT enablement and remote data capture.
- Curebase: Curebase is a decentralized clinical trial platform providing ePRO, remote monitoring, and home-based assessments. It competes with Valis in DCT delivery for CNS and rare disease sponsors seeking patient-centric, technology-driven trial designs.
Direct peers
- Signant Health: Signant Health (formerly Bracket) provides eCOA/ePRO, rater training and certification, and decentralized clinical trial solutions, directly overlapping with ValisR, ACAM, ePRO/eDiary, and the Trial.training platform. Signant is the closest large-scale direct peer in CNS measurement and rater enablement.
- Clario: Clario (formed from ERT and Bioclinica) offers eCOA, electronic clinical outcome assessment, imaging, and respiratory solutions across CNS, oncology, and rare disease trials. Its eCOA and rater training portfolio directly competes with Valis's measurement and certification offerings.
Broad incumbents
- Veeva Systems: Veeva Vault CDB and Veeva ePRO compete with Valis's clinical data and eCOA offerings, particularly for sponsors standardizing on the Veeva platform across CTMS, EDC, and eCOA. It is a broad incumbent with deep enterprise relationships.
- IQVIA eCOA: IQVIA provides eCOA, EDC, and full-service clinical trial operations including rater training and CNS expertise. Its scale and CNS delivery capability make it a broad incumbent competitor for the same enterprise pharma clients Valis targets.
- WCG (WIRB-Copernicus Group): WCG provides clinical trial technology, eCOA, and CNS-focused rater enablement services through its Clinical Endpoint Solutions business. It competes for the same sponsor training and central rating budgets that Valis pursues with Trial.training.
- Medidata Solutions: Medidata (Dassault Systèmes) is a broad clinical trial platform with Rave EDC, eCOA, and DCT modules serving global pharma sponsors. It is a larger incumbent alternative for sponsors evaluating Valis's ePRO and centralized assessment capabilities.
- Oracle Health Sciences: Oracle Health Sciences (formerly Phase Forward) provides EDC, ePRO, and clinical trial analytics to large pharma. As a broad incumbent, it represents the 'build vs. buy' alternative for sponsors considering a specialist like Valis.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Valis Bioscience social profiles
Digital presenceValis Bioscience compliance and trust
Trust signalCompliance5 records
Valis Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Valis Bioscience leadership team
Management profileNumber of profiles
Profiles2 records
Valis Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Valis Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Valis Bioscience
What does Valis Bioscience do?
Valis Bioscience develops and licenses proprietary clinical research technology for psychiatric and neurological disorder trials, centered on the ValisR digital health platform. Its offerings include a HIPAA-compliant remote video assessment platform, the ACAM hardware+software video capture and scoring module, custom ePRO/eDiary applications, rater training and certification via the Trial.training portal, mobile health applications, and scientific/endpoint consulting services sold to pharmaceutical companies, biotech firms, and clinical trial sponsors.
Is Valis Bioscience a public or private company?
Valis Bioscience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Valis Bioscience founded?
Valis Bioscience was founded in 2016. It employs 1 to 10 people.
Where is Valis Bioscience based?
Valis Bioscience is headquartered in Berkeley, United States, in the North America region.
How does Valis Bioscience make money?
Three revenue lines are on record. Technology Platform Licensing is the primary driver. The others are professional Services - Rater Training and mobile Health Application Deployment.
Who are Valis Bioscience's main competitors?
Emerging players on record are Aural Analytics, Medable and Curebase. Direct peers are Signant Health and Clario. Broad incumbents are Veeva Systems, IQVIA eCOA, WCG (WIRB-Copernicus Group), Medidata Solutions and Oracle Health Sciences.
Does Valis Bioscience have an API?
No public API is recorded for Valis Bioscience.
What industry is Valis Bioscience in?
Valis Bioscience's product category is Clinical Trial Technology (eClinical / CNS measurement). Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 5132 and its SIC code is 7372.